AssetMark’s AnaptysBio ANAB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.11K Buy
42
+6
+17% +$339 ﹤0.01% 3034
2026
Q2
$2.43K Hold
36
– – ﹤0.01% 2917
2026
Q1
$2K Hold
36
– – ﹤0.01% 2856
2025
Q4
$1.74K Hold
36
– – ﹤0.01% 2802
2025
Q3
$1.1K Hold
36
– – ﹤0.01% 2761
2025
Q2
$799 Buy
+36
New +$754 ﹤0.01% 2655

Other funds holding ANAB

AssetMark's ANAB Position: Q3 2026 in Review

AssetMark increased its AnaptysBio (ANAB) stake by 17% in Q3 2026, buying an estimated $339 and bringing the position to 42 shares worth $2.11K. The position accounts for ﹤0.01% of the portfolio, ranked #3034.

AssetMark first reported a position in ANAB in Q2 2025 and has held it in 6 quarters since. The position peaked at $2.43K in Q2 2026. 160 funds tracked by Wall St. Rank hold ANAB as of Q3 2026.

  • AssetMark held 42 shares of AnaptysBio worth $2.11K as of Q3 2026.
  • AssetMark bought 6 AnaptysBio shares in Q3 2026, an estimated $339.
  • AnaptysBio made up ﹤0.01% of AssetMark's portfolio in Q3 2026, its #3034 holding.
  • AssetMark first reported a position in AnaptysBio in Q2 2025 and has held it in 6 quarters since.
  • AssetMark's AnaptysBio position peaked at $2.43K in Q2 2026.
  • 160 funds tracked by Wall St. Rank held AnaptysBio as of Q3 2026.

Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.